2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 031

Clinical Characteristics and Diagnostic Predictors of Inflammatory Bowel Disease in Patients with Chronic Nonbacterial Osteomyelitis – A Single Center Retrospective Analysis
Abstract Number: 106

Clinical Characteristics and Safety Outcomes in Refractory Kawasaki Disease Treated with Second-Dose Infliximab
Abstract Number: 048

Clinical characteristics of childhood-onset primary Sjögren’s syndrome in South Korea: two centers’ experiences
Abstract Number: 099

Clinical Features of Juvenile Antisynthetase Syndrome: A Single-Center Case Series
Abstract Number: 138

Demographic, Clinical and Major Histocompatibility Complex (MHC) variation associated with uveitis development in children with juvenile idiopathic arthritis
Abstract Number: 088

Demographics and Clinical Features of Deficiency of adenosine deaminase 2: A Large Quaternary Single Center Experience
Abstract Number: 078

Development of A High-Parameter Whole Blood Thrombo-inflammation Flow Cytometry Panel for Research in Pediatric Autoimmune Diseases
Abstract Number: 051

Do Changes in the Weather Influence Joint Pain and Stiffness in Children with Juvenile Idiopathic Arthritis?
Abstract Number: 003

Dysregulated Macrophage–Fibroblast Crosstalk Identified by Single-Cell RNA-seq in Juvenile Systemic Scleroderma Skin
Abstract Number: 084

Early Life Exposures and Risk of Spondyloarthritis: A Population-Based Case-Control Study
Abstract Number: 125

Educational Interventions to Increase Transition Preparedness in a Pediatric Rheumatology Clinic
Abstract Number: 019

Effects of Childhood-Onset Interferon-Driven Autoimmune Disorders on Brain Volume and Executive Function: A Pilot Analysis in JDM and Childhood-Onset SLE
Abstract Number: 010

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 044

Efficacy of Rituximab Biosimilars in Pediatric ANCA-Associated Vasculitis
Abstract Number: 070

Empowering Voices: Inception of a Parent Led Anatomical Visual Pain Assessment Tool for Juvenile Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].